The European Commission's August 2026 dairy report put the EU whey powder quote at €167 (about US$194) per 100 kilograms, 70 percent above a year earlier. That commodity figure cannot predict a retail supplement price, but package labels allow buyers to compare the amount paid for each gram of protein.
The US Federal Trade Commission finalized an order on July 15, 2026 against a supplement seller and two officers over allegedly deceptive growth claims and employee or incentivized reviews. Across markets, an endorsement does not supply evidence for a food claim, and responsibility depends on who controlled, created or distributed the message.
An April 2026 BMJ Open audit rated 49.6 percent of 250 responses from five consumer chatbots as problematic when tested with misinformation-prone health prompts. Consumers can reduce that risk by checking the exact claim against regulator records, matching it to human evidence and opening every cited source.
A July 2026 review found only low- or very-low-certainty evidence for exosome-based nonsurgical facial rejuvenation. Evidence for products labeled with exosomes, NAD+, stem cells or peptides depends on the formulation, route and outcome, not the laboratory term alone.
World Medical Association guidance reaffirmed in October 2024 tells physicians to give evidence-based information and avoid recommending unproven products in media. A doctor's appearance, a ‘clinically proven’ label and a patent answer different questions, and none alone establishes a supplement's claimed effect.
The European Union's 2024 annual report said a screening found that 97 percent of the influencers checked posted commercial content, but only one in five consistently identified it as advertising. For supplement posts, a sponsorship label identifies a commercial tie; it does not show that a health claim matches regulator records or human evidence.
Codex Alimentarius guidance treats “natural” and absence claims as conditional marketing claims, not proof that a packaged food is safer or more nutritious. The ingredient list provides more specific evidence, but national rules determine how each claim and additive must be declared.
Evidence reviews do not support commercial detox programs for removing toxins or alkaline diets for preventing cancer. Ketogenic diets are established treatments for some cases of epilepsy, but weight-loss evidence and safety depend on the regimen and the person using it.
European food-safety assessors said in 2025 that available evidence still could not establish a safe daily intake of monacolins from red yeast rice supplements. Monacolin K is structurally identical to lovastatin, and products may vary in strength and contamination risk.
The World Gastroenterology Organisation's 2023 guideline says probiotic benefits should be tied to a named strain or strain combination at an effective dose. A large CFU count alone cannot show that a product matches the evidence or will remain potent through its shelf life.
The AREDS2 primary analysis did not show that adding lutein and zeaxanthin reduced progression to late age-related macular degeneration. Later findings apply to people who already had intermediate disease or late disease in one eye, not to healthy screen users.
A 2025 meta-analysis of 23 randomized trials found no improvement in skin hydration, elasticity or wrinkles when researchers examined higher-quality studies separately. Favorable results were concentrated in lower-quality and pharmaceutical-company-funded trials, leaving the clinical case for collagen supplements unresolved.
A 2024 analysis of three COSMOS substudies found a small cognitive difference among older US adults assigned a daily multivitamin. The parent trial found no reduction in total cancer, cardiovascular disease or all-cause mortality.
A 2026 evidence review found that oral NMN changes NAD-related biomarkers, while its effects on health and physical function remain inconsistent. Taiwan also bars food advertising from claiming medical efficacy, making product legality a separate question from clinical benefit.
European cardiology guidelines retained risk-based LDL cholesterol targets in 2025, ranging from below 116 mg/dL for low-risk adults to below 55 mg/dL for those at very high risk. The figures are treatment goals within a European framework, not universal laboratory reference ranges.
